Anika Therapeutics | ANIK - Current Assets


Anika Therapeutics reported $93.56M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Agenus USD 133.44M 514K Dec/2025
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Anika Therapeutics USD 93.56M 9.8M Mar/2026
Arrowhead Research USD 1.17B 223.75M Dec/2025
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Heron Therapeutics USD 238.07M 8.67M Dec/2025
Insmed USD 1.79B 137.6M Dec/2025
Integra LifeSciences USD 1.17B 12.47M Mar/2026
Intrexon USD 23.72M 45.04M Jun/2024
J&J USD 59.17B 3.55B Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Ligand Pharmaceuticals USD 832.27M 78.35M Dec/2025
MacroGenics USD 219.94M 12.15M Dec/2025
Merit Medical Systems USD 1.1B 61.62M Mar/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.16B 789M Mar/2026
Smith & Nephew USD 4.63B 169M Dec/2025
Stryker USD 13.34B 1.42B Mar/2026
Surmodics USD 75.99M 5.31M Jun/2025
Veracyte USD 488.38M 39.15M Dec/2025
Xencor USD 599.82M 81.38M Dec/2025
Zimmer Biomet Holdings USD 4.96B 157.4M Mar/2026